Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

MBX Biosciences (MBX) Profit After Tax (2023 - 2026)

MBX Biosciences has reported Profit After Tax over the past 4 years, most recently at -$23.5 million for Q1 2026.

  • Quarterly results put Profit After Tax at -$23.5 million for Q1 2026, up 1.59% from a year ago — trailing twelve months through Mar 2026 was -$86.6 million (down 17.94% YoY), and the annual figure for FY2025 was -$87.0 million, down 40.55%.
  • Profit After Tax reached -$23.5 million in Q1 2026 per MBX's latest filing, down from -$22.1 million in the prior quarter.
  • Across five years, Profit After Tax topped out at -$8.8 million in Q4 2023 and bottomed at -$23.9 million in Q1 2025.
  • Median Profit After Tax over the past 4 years was -$18.1 million (2024), compared with a mean of -$17.4 million.
  • The largest annual shift saw Profit After Tax crashed 93.56% in 2025 before it grew 1.59% in 2026.
  • Over 4 years, Profit After Tax stood at -$8.8 million in 2023, then tumbled by 76.0% to -$15.6 million in 2024, then plummeted by 41.94% to -$22.1 million in 2025, then fell by 6.38% to -$23.5 million in 2026.
  • Business Quant data shows Profit After Tax for MBX at -$23.5 million in Q1 2026, -$22.1 million in Q4 2025, and -$21.6 million in Q3 2025.